The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

By Andreas Rosenwald, A. Wiestner, Wing C. Chan, J. Connors, George W. Wright, E. Campo, R. Gascoyne, Thomas M. Grogan, Konrad Muller-Hermelink, E. Smeland and 30 more. Cancer Cell, 2003

970 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/83d6c39f6044f2f4cfbde6f4b00aed7e483448b8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma (2013, background): “Interestingly, WHSC1-mutated MCL showed a highly significant overexpression of the gene signature up-regulated in PCM with the t(4;14) translocation overexpressing WHSC1 (17).”
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma (2003, methodology): “Quantitative PCR assays were used to assess the genomic copy number of the PDL2 gene relative to the control PRKCQ gene, as described (18).”
Cyclin D as a therapeutic target in cancer (2011, background): “In MCL CCND1 mRNA expression correlates with a proliferation signature that is comprised of genes that are expressed at higher levels in dividing cells than in quiescent cells, with the highest levels of proliferation or cyclin D1 expression associated with the poorest overall surviva”
High-dimensional additive hazards models and the Lasso (2011, methodology): “This can be a problem since, in practice, one can not, in general, consider that the asymptotic regime has been reached: in [30], for example, the expression levels of 8810 genes and survival information are measured for only 92”
The tor pathway: a target for cancer therapy (2004, background): “Similarly, there might be tumours, such as mantle-cell lymphomas, that are characterized by overexpression of cyclin D1 (Ref”
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma (2010, positive): “Higher CD47 expression was also associated with unmutated immunoglobulin heavy chain variable regions (IgVH) in CLL (Figure 1G and Figure S1E) and significantly correlated with the proliferative index in MCL (Figure 1H), both known adverse prognostic factors (Katzenberger et al., 2006; Oscier et al.”
Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells (2009, positive): “This proposal is in agreement with the report on mantle cell lymphomas, in which the patients that have shorter Cyclin D1 30UTRs have the worst prognosis (Rosenwald et al., 2003; Wiestner et al., 2007).”